Skip to content

Electrical Stimulation and Expression of VEGF and NO in Diabetic Foot Ulcer

The Effect of Low-intensity Direct Current on the Expression of Vascular Endothelial Growth Factor and Nitric Oxide in Diabetic Foot Ulcers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02019082
Enrollment
20
Registered
2013-12-24
Start date
2011-03-31
Completion date
2011-12-31
Last updated
2013-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer

Brief summary

This study aimed to investigate the effect of low intensity cathodal direct current on the release of plasma vascular endothelial growth factor (VEGF) and nitric oxide (NO) in diabetic foot ulceration.

Detailed description

Twenty type 2 diabetic patients with foot ulceration and 13 age-matched healthy subjects were enrolled. Patients were randomly assigned to electrical stimulation (ES, n=10) or sham ES (placebo, n=10) groups. ES group received cathodal direct current for 1 h/day, 3 days/week, for 4 weeks (12 sessions). Blood sample was collected for VEGF and NO measurement in the first and last treatment sessions before and after intervention. Wound surface area (WSA) and skin temperature were measured at 1st, 6th, and 12th session.

Interventions

DEVICEElectrical Stimulation (BTL-5000 series, United Kingdom)

Direct current ES

DEVICEplacebo

the intervention procedure was the same as that the ES group, but the current intensity was zero

Sponsors

giti torkaman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Wagner classification DFU 2; * age 40-60 years; * mild to moderate diabetic neuropathy; * ABI\>0.7 * wound surface area\>1.5cm2

Exclusion criteria

* fracture in a lower limb, * a severe infection, * a malignancy, * kidney failure, * skin diseases, * osteomyelitis, * pregnancy,

Design outcomes

Primary

MeasureTime frame
The plasma level of VEGF(pg/ml) and NO (microM)prior to the 1st electrical stimulation session(day 1) and 1 hour later, and prior to the 12th electrical stimulation session(day 26) and 1 hour later

Secondary

MeasureTime frame
skin temperature (degree of centigrade)prior the 1st electrical stimulation session (day 1) and 1 hour later
Wound surface area(cm2)on day 1, 12, and 26

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026